









Markets
/
Stocks
/
nasdaq-exel
/

Exelixis Inc

EXEL

41.570USD

+0.160+0.39%

Close 03/24, 16:00（ET）Quotes delayed by 15 min

6.17BMarket Cap

14.43P/E TTM



Exelixis Inc

41.570

+0.160+0.39%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Exelixis Inc

Currency: USD Updated: 2026-03-24

Key Insights

Exelixis Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 10 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 46.83.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Exelixis Inc's Score

Industry at a Glance

Industry Ranking

10 / 391

Overall Ranking

75 / 4547

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Exelixis Inc Highlights

StrengthsRisks

Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 26.77% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 2.32B.

Undervalued

The company’s latest PE is 14.43, at a low 3-year percentile range.

Held by Ray Dalio

Star Investor Ray Dalio holds 925.71K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.11.

Analyst Rating

Based on 21 analysts

Buy

Current Rating

46.833

Target Price

+13.48%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-24

The current financial score of Exelixis Inc is 9.18, ranking 10 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 598.66M, representing a year-over-year increase of 5.63%, while its net profit experienced a year-over-year increase of 74.84%.

Score

Industry at a Glance

Previous score

9.18

Change



Financials

9.23

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.79

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.87

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Exelixis Inc's Company Valuation

Currency: USD Updated: 2026-03-24

The current valuation score of Exelixis Inc is 7.03, ranking 181 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is 14.43, which is 486.18% below the recent high of 84.56 and 2.00% above the recent low of 14.14.

Score

Industry at a Glance

Previous score

7.03

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 10/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-24

The current earnings forecast score of Exelixis Inc is 7.24, ranking 306 out of 391 in the Biotechnology & Medical Research industry. The average price target is 45.50, with a high of 60.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

7.24

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 21 analysts

Buy

Current Rating

46.833

Target Price

+13.48%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Exelixis Inc

EXEL

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-24

The current price momentum score of Exelixis Inc is 7.08, ranking 81 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 45.06 and the support level at 38.90, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.17

Change

-0.09

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.066

Neutral

RSI(14)

45.778

Neutral

STOCH(KDJ)(9,3,3)

54.062

Buy

ATR(14)

1.082

Low Volatility

CCI(14)

8.499

Neutral

Williams %R

45.155

Neutral

TRIX(12,20)

-0.216

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

41.354

Buy

MA10

41.383

Buy

MA20

41.843

Sell

MA50

42.939

Sell

MA100

42.808

Sell

MA200

41.559

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-24

The current institutional shareholding score of Exelixis Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 98.50%, representing a quarter-over-quarter decrease of 1.36%. The largest institutional shareholder is The Vanguard, holding a total of 25.43M shares, representing 9.79% of shares outstanding, with 6.68% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

25.01M

-1.68%

The Vanguard Group, Inc.

Star Investors

26.00M

-5.14%

Farallon Capital Management, L.L.C.

19.50M

+21.61%

Renaissance Technologies LLC

Star Investors

15.46M

-2.28%

AQR Capital Management, LLC

9.18M

+20.71%

State Street Investment Management (US)

11.11M

-2.37%

Fuller & Thaler Asset Management Inc.

8.32M

-5.18%

LSV Asset Management

7.77M

-0.66%

Geode Capital Management, L.L.C.

7.67M

+3.03%

Arrowstreet Capital, Limited Partnership

5.27M

+0.10%

Risk Assessment

Currency: USD Updated: 2026-03-24

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Exelixis Inc is 7.37, ranking 13 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.44. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.